Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of genetic variants on the pharmacokinetics and pharmacodynamics of sirolimus: a systematic review.

Pharmacogenomics - 1 Jul 2023

Wm Te Loo D Maroeska, Harbers Veroniek, Vermeltfoort Lars, Coenen Marieke Jh

Abstract excerpt

Sirolimus is an antiproliferative and immunosuppressive compound inhibiting the mTOR pathway, which is often activated in congenital low-flow vascular malformations. Studies have demonstrated the efficacy of sirolimus for this disease. Studies in kidney transplant patients suggest that genetic variants can influence these pharmacokinetic parameters. Therefore, a systematic literature search was performed to gain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Transplantation

Share to Polymorphism, Single Nucleotide

Share to Sirolimus

Share to Tacrolimus

Source

Identifiers

PMID: 37551646
DOI: 10.2217/pgs-2022-0147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of genetic variants on the pharmacokinetics and pharmacodynamics of sirolimus: a systematic review.PMID 37551646Read ↗

How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.Semantic proximity Read ↗

New and Emerging Targeted Therapies for Vascular Malformations.Semantic proximity Read ↗

Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.Semantic proximity Read ↗

Targeted Therapies for Slow‐Flow Vascular MalformationsSemantic proximity Read ↗

Optimal dosing for vascular anomalies pediatric patients with population pharmacokinetic model of sirolimusSemantic proximity Read ↗

Rapamycin and treatment of venous malformationsSemantic proximity Read ↗

Genotype-guided medical treatment of arteriovenous malformation.Semantic proximity Read ↗

Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation.Semantic proximity Read ↗

Long term treatment of sirolimus for pediatric vascular anomalySemantic proximity Read ↗

Correlation between the miR-618 rs2682818 C>A polymorphism and venous malformation susceptibility.Semantic proximity Read ↗

Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: preliminary pharmacokinetics and pharmacodynamic dataSemantic proximity Read ↗

Analysis of genetic polymorphism and biochemical characterization of a functionally decreased variant in prostacyclin synthase gene (CYP8A1) in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.